// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























914 Abstracts

Identification and PK/PD Assessment of an Oral, Selective, avb6/ avb1 Dual Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis

S. Turner - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Exploration of Novel Biomarkers of Fibrosis by Proteomics of Exosomes

T. Matsuki - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

Induced Pulmonary Fibrosis Through Multifaceted Mechanisms

X. Cong - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

3 Plasma Levels and Secretion Mechanism in Idiopathic Pulmonary Fibrosis

G. Shaughnessy - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Site Sampling in Understanding the Pathogenesis of Idiopathic Pulmonary Fibrosis

J. Fukumoto - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

Protein C

1R Pathway in Idiopathic Pulmonary Fibrosis

M. S. Espindola - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

AEW541

Nintedanib Treatment for Elderly Patients with Idiopathic Pulmonary Fibrosis

Y. Ochi - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

A Multicenter Study for the Evaluation of Effectiveness and Safety of Nintendanib in the Treatment of Idiopathic Pulmonary Fibrosis

K. Antoniou - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

Nintedanib

Efficacy and Safety of Pirfenidone in Idiopathic Pulmonary Fibrosis According to Dose and Disease Severity

J. Park - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Dose Prednisolone with Pirfenidone in Idiopathic Pulmonary Fibrosis

S. Matsubayashi - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Glucocorticoid

The Effect of Nintedanib on Clinical Outcome of 158 Patients with Idiopathic Pulmonary Fibrosis in Real World Settings

M. Dobashi - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

Life Setting

O. Nishiyama - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

Analysis of Effectiveness of Pirfenidone in Subgroups of Idiopathic Pulmonary Fibrosis Based on Real World Data from European IPF Registry

E. Krauss - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Medication Discontinuation and Survival in Elderly Veterans on Antifibrotics for Idiopathic Pulmonary Fibrosis

J. Ryan - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Randomized Phase 2 Study of Nintedanib with or Without Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Who Experienced a Clinically Meaningful Decline in Forced Vital Capacity During Prior Pirfenidone Administration

S. Ikeda - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Dosage Reduce the Early Termination of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

S. Ikeda - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

World Canadian Cohort of Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone

C. Ryerson - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Anticipatory Grief in Idiopathic Pulmonary Fibrosis (IPF) Patients and Their Caregivers

D. G. Sandford - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Idiopathic pulmonary fibrosis

N/A

Fibrotic Drug Prescription in a Veteran Population for Idiopathic Pulmonary Fibrosis

B. Moss - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Timing and Frequency of Cardiopulmonary Testing in Persons with Idiopathic Pulmonary Fibrosis

C. Holtze - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Copyright © 2026. QuantiNova All rights reserved